Tvardi Therapeutics, Inc. Updates on Phase 2 REVERT Trial Results
Less than 1 min read
On October 13, 2025, Tvardi Therapeutics, Inc. announced preliminary data from its Phase 2 REVERT trial in idiopathic pulmonary fibrosis.
Key Highlights:
- Phase 2 trial of TTI-101 did not meet its primary goals.
- High discontinuation rates due to gastrointestinal events in treatment arms.
- No significant differences in FVC changes between placebo and treatment groups.
- Company plans further analysis to understand trial results.
- Tvardi remains on track for 2026 data from TTI-109 and TTI-101 trials.
Original SEC Filing: Tvardi Therapeutics, Inc. [ TVRD ] - 8-K - Oct. 14, 2025
AI-powered summaries may contain inaccuracies. Consider verifying important information with the source.